BIO-TECHNE Corp. (TECH) intrinsic value & 10-year financials
BIO-TECHNE Corp. (TECH) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 10.4% a year to $1.2B, with an average return on invested capital of 10.1%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $72.57
- Market cap
- $11.6B
- Revenue (FY2025)
- $1.2B
- Revenue growth (10-yr CAGR)
- 10.4%
- ROIC (10-yr avg)
- 10.1%
- Free cash flow (FY2025)
- $256.6M
TECH 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $1.2B | $73.4M | $0.46 | $256.6M | 8.4% | 3.5% |
| FY2024 | $1.2B | $168.1M | $1.05 | $236.1M | 17.8% | 8.6% |
| FY2023 | $1.1B | $285.3M | $1.76 | $216.1M | 26.3% | 12.9% |
| FY2022 | $1.1B | $272.1M | $1.66 | $280.4M | 26.8% | 15.0% |
| FY2021 | $931.0M | $140.4M | $0.87 | $307.9M | 25.5% | 13.7% |
| FY2020 | $738.7M | $229.3M | $1.46 | $153.5M | 21.3% | 8.3% |
| FY2019 | $714.0M | $96.1M | $0.62 | $156.2M | 20.5% | 8.8% |
| FY2018 | $643.0M | $126.2M | $0.83 | $149.4M | 21.2% | 10.9% |
| FY2017 | $563.0M | $76.1M | $0.51 | $128.5M | 21.4% | 7.8% |
| FY2016 | $499.0M | $104.5M | $0.70 | $127.3M | 30.2% | 11.8% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Bio-Techne is a consistent compounder, expanding top-line revenue at 10.4% annually over the past decade.
Bio-Techne returns on capital have been average, hovering around 10.1% ROIC over the decade.
Over the decade, Bio-Techne shows that the company has leveraged its balance sheet to sustain operations.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Bio-Techne is modeled at -4.6% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-0.25 per share.